Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Product type:GuidanceProgramme:Technology appraisal guidanceExpected publication date: 24 May 2019
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 30 October 2019
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 24 May 2019
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 9 January 2019
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 19 December 2018
Sorafenib for treating advanced hepatocellular carcinoma (TA474)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 6 September 2017
Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 August 2021
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [ID1655]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC